Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated (ATTR) amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.

AstraZeneca licensed the candidate, called cliramitug or NI006, from Neurimmune in 2022. That deal gave the Swiss biotech $30 million upfront, with the potential for up to $730 million in development, regulatory and commercial milestones, as well as “low-to-mid teen royalties on net sales” should cliramitug make it to market.